Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab

Creators

• Bouhlel, Linda
• Doyen, Jérôme
• Chamorey, Emmanuel
• Poudenx, Michel
• Ilie, Marius
• Gal, Jocelyn
• Guigay, Joël
• Benzaquen, Jonathan
• Marquette, Charles-Hugo
• Berthet, Jean-Philippe
• Mouroux, Jérôme
• Schiappa, Renaud
• Padovani, Bernard
• Hofman, Paul
• Otto, Josiane

Contributors